Most Read Articles
05 Aug 2017
Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.
Roshini Claire Anthony, 15 hours ago

Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.

03 Aug 2017
Cetuximab and docetaxel is safe and effective during postoperative radiotherapy for high-risk head and neck cancer patients who cannot receive cisplatin, a new study has found.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.

Certain neovascular AMD patients may benefit from second-line aflibercept therapy

06 Jul 2017

Neovascular age-related macular degeneration (nvAMD) patients with inadequate response to initial bevacizumab therapy may benefit from an early switch to aflibercept therapy, which has been demonstrated to improve best corrected visual acuity (BCVA) and reduce central subfield thickness (CST).

In the Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI), three monthly intravitreal aflibercept 2 mg injections were administered, followed by two bimonthly injections and a final examination at week 28 (with an optional injection allowed at week 20) to 47 eyes of 46 patients (mean age 76 years). All eyes had incomplete response to between three and nine prior bevacizumab injections (mean, 5.5).

At week 28, the mean visual acuity improved from 60.3 Early Treatment Diabetic Retinopathy Study letters at baseline to 63.1 letters (p=0.02). Moreover, the CST decreased from 409 microns at baseline to 330 microns at week 4 (p=0.0002) and 277 microns at week 28 (p=0.00002).

Prior bevacizumab injections ranged between three and five in 22 eyes (mean, 5.1 injections) and between six and nine in 25 eyes (mean, 7.32±1.2). CST decreased from baseline in both groups at week 28 (p=0.0004 and p=0.0007, respectively). More than half of the eyes (75 percent) required the optional additional aflibercept injection at week 20.

Antivascular endothelial growth factor (VEGF) compounds, administered intravitreally, have been shown to have favourable effect on the short- and intermediate-term outcome of nvAMD. Compared with bevacizumab and ranibizumab, aflibercept has higher binding affinity for VEGF-A by binding to placental growth factors 1 and 2 and VEGF-B, researchers noted.

In addition, aflibercept has a longer half-life in the vitreous as compared with ranibizumab. [Angiogenesis 2012;15:171–185; Invest Ophthalmol Vis Sci 2003;44:3186–3193]

The present data suggest that aflibercept improves anatomical and visual outcome in nvAMD eyes with incomplete response to first-line bevacizumab therapy.

“Majority of eyes required monthly second-line aflibercept therapy during the first 6 months to preserve a fluid-free macula,” researchers said. “Magnitude of anatomical and visual response may be similar regardless whether second-line therapy is commenced after few months of first-line therapy or later. Yet, final outcome may depend on the initial visual acuity.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
05 Aug 2017
Discontinuation of antihypertensive drugs appears to have a detrimental effect, with a recent study reporting that the risk of acute myocardial infarction (AMI) substantially increases after more than 90 days of discontinuation.
Roshini Claire Anthony, 15 hours ago

Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.

03 Aug 2017
Cetuximab and docetaxel is safe and effective during postoperative radiotherapy for high-risk head and neck cancer patients who cannot receive cisplatin, a new study has found.
08 Sep 2017
Prediagnostic statin exposure appears to be associated with a significant reduction in breast cancer-specific mortality, with the survival benefit being more pronounced in women with oestrogen receptor (ER)-positive tumours, according to a study.